Our results clearly demonstrated that Y-142 inhibits sHB-EGF-induced cancer cell proliferation as well as sHB-EGF-induced angiogenic processes more effectively than cetuximab and CRM197, suggesting that Y-142 may have more promising therapeutic possibilities than cetuximab and CRM197. Here, EGF is linked to cancer.